9th Annual Biomarkers Congress

Drug Design: AstraZeneca

Total Score People Score Events Score
105 99 70
Date Event Presentation Speakers
June 4, 2013 World Pharma Congress Cellular Impedance Measures of Cardiomyocyte Cultures for Screening Kinase Inhibitors Matthew Peters
FEATURED PRESENTATION: Predicting, Minimizing and Avoiding Human Adverse Drug Reactions Gerry Kenna
November 29, 2010 2nd Joint DIA/ European Medicines Agency Innovation Forum: Is the EU Regulatory Framework Ready? Presentation By Solange Corriol Rohou Solange Corriol Rohou
November 3, 2010 DIA’s 8th Annual Canadian Meeting: “Keeping Canada on the Map: Fostering Innovation and Access to Drugs in Canada� Opening Plenary Session Karen Feltmate
Globalization of Supply Chain – Pro’s and Con’s, Making Manufacturing Changes on a Global Scale, Regulatory Hurdles and Impacts on Product Availability Dean Callaghan
Patient Retention Strategies in Long Term Clinical Trials: Challenges and Ethical Considerations Sandra Smyth
Panel Discussion: “Ask the Regulators” Karen Feltmate
August 23, 2010 The Ubiquitin Drug Discovery & Diagnostics Conference Ubiquitin Specific Proteases as novel drug targets – A case study Jonathan D. Wrigley
May 4, 2010 Biomarker World Congress 2010 New Era with Targeted Drugs: New Development Approaches are Needed to Achieve Success Geert J.C.M. Kolvenbag
April 6, 2010 IBCs 5th Annual China 2010 Pharmaceutical R&D Summit 4 Case Study: Conducting Proof-of-Concept Studies in China Karen Atkin
February 24, 2010 5th Annual Bioanalysis in Clinical Research An approach to the validation of flow cytometry methods in the regulatory environment Ruth Coldwell
Validation and subsequent application of an immunoassay method for the determination of GRO-alpha in human serum Karen Elsby
February 22, 2010 2010 PERSONALIZED MEDICINE PARTNERSHIPS CONFERENCE Strengthening Big Pharma's Personalized Medicine Pipeline via Partnerships with Diagnostics Companies Cecilia Schott
November 2, 2009 Seventh Annual Strategic Resource Management TABLE 7: Aligning Portfolio & Productivity with Corporate Strategy Mellor Hennessy
TABLE 3: Visualization of Management Information Anders Persson
TABLE 1: Modeling the Portfolio of the Future: Will Today’s Cycle Time, Attrition, and Cost Models Remain Valid? James F. Resch
Capacity Management: The Behaviors Necessary for Success Anders Persson
November 2, 2009 Track 6: Third Annual Kinase Inhibitors Developing a Novel Checkpoint Kinase Inhibitor Sonya Zabludoff
November 2, 2009 Track 3: Fourth Annual Ion Channels as Therapeutic Targets Lead Generation and Postdocs in the Pharmaceutical Industry – Lessons Learned Michael Dabrowski
August 24, 2009 Specialized Protein Expression Systems In vivo Encapsulation of Recombinant Proteins as Universal Production Platform Stefan R. Schmidt
Chairperson’s Remarks Stefan R. Schmidt
August 5, 2009 Targets in Context - Linking Targets to Diseases Agenda Comparison of Whole-Cell, Label-Free Assays for GPCR Drug Discovery Matthew Peters
August 5, 2009 Drug Safety Strategies to De-Risk Compounds Developing Computational Biology in Toxicology: Predictions, Data and Culture Sherri Matis-Mitchell
How Can Systems Biology Help in De-risking Molecules? David Cook
July 1, 2009 Advances in Oral Dose Manufacturing Overcoming Solubility Challenges in Developing OSD Products George Kirk
Understanding the Coating Process for Multiparticulate Formulations Staffan Schantz
June 10, 2009 Second Annual Hepatotoxicity and Drug Safety Monitoring Hepatotoxicity in Clinical Trials Mark H. Steinberg
June 9, 2009 Inaugural The Expanding Impact of New Animal Models in Drug Safety Biomarkers of Functional Toxicities: Identification and Assessment of their Translation into Humans Jean-Pierre Valentin
Zebrafish Assays as Early Safety Pharmacology Screens: Paradigm Shift or Red Herring? Jean-Pierre Valentin
June 9, 2009 Cell and Tissue-Based Assays for HTS Screening Bone Marrow Toxicity Using a Tiered Approach David Brott
June 9, 2009 Targeting Pain with Novel Therapeutics Cannabinoid-based Analgesia without Central Side-effects: CB2 Selective Agonists versus Peripherally Restricted CB1 Agonists Thierry Groblewski
Table Three: Targeting Inflammatory Pain Thierry Groblewski
June 4, 2009 Structure-Based Drug Design Supplementing Structural Information with Biophysical Data: Adding Value and Understanding in Lead Generation Stefan Geschwindner
Designing Drugs against Multiple Parameters: Scoring Functions for Multi-Parameter Ligand Based De Novo Design James R. Damewood
May 19, 2009 Amorphous Materials Amorphous Nanoparticles of Poorly Soluble Drugs Lennart , Lindfors
Detection and Quantification of Low Amounts of Amorphous Materials Kjell Jarring
May 12, 2009 BioAvailability and BioEquivalence Biorelevant Technologies to Support Formulations Destined for the Clinic Gorkhn Sharma-Singh
April 7, 2009 Kinase Inhibitor Chemistry - Charting the Chemical Space Identification of Potent and Selective Inhibitors of Trk Kinases Tao Wang
April 1, 2009 Stability Testing Industry Perspective: Susan Smith
February 24, 2009 Pharmaceutical Analysis Course Drug discovery with a pinch of salt Andrew Robbins
Strategies for chiral analysis Des Dalton
Use of modern spectroscopic techniques in the elucidation of molecule structure Simon de Sousa
Getting to grips with the genotoxic impurity analysis Andrew Baker
February 23, 2009 4th Investigator Relationship Management INVESTIGATOR SELECTION Arthur Lazarus
February 23, 2009 Advances and Progress in Drug Design VIII QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIPS Rupert Austin
February 6, 2009 9th Investigator Initiated Trials IISRA WORKING GROUP Karen Bartels
NEW PHARMA CASE STUDY : Case Study: IIT Document Management Susan Watson
February 4, 2009 Adaptive Designs in Clinical Drug Development IMPLEMENTING DOSE RANGING STUDIES Frank Miller
CONSIDERING OPERATIONAL ASPECTS OF AN ADAPTIVE DESIGN STUDY Helen Eastham
January 28, 2009 Electronic Laboratory Notebooks USER REQUIREMENTS : Creating a simple transition from paper to electronic Ian Menzies
January 27, 2009 6th Annual Clinical Trial Performance Metrics Maximising the return on investment of clinical trials metrics – using metrics to implement process improvement to improve delivery and productivity in Clinical Trials Diane Dootson
Keynote: How AstraZeneca is approaching metrics concerning patient recruitment Niclas Pantzar
Investigator metrics – how metrics can help to improve investigator performance Ramil Abdrachitov
January 27, 2009 4th Annual Aseptic Filling and Processing Case study 1: Changes to the airborne particulate classification table – interpretation and practical issues for cleanroom operation Tim Eaton
January 27, 2009 Forced Degradation Studies Design of forced degradation studies for small molecules in drug discovery Philip MacFaul
Opening remarks by the Chairperson Thomas Andersson
Understanding how APIs and excipients degrade in formulations Thomas Andersson
January 26, 2009 Translational Cancer Medicine VANDETANIB : Pretreatment Circulating VEGF Levels as A Predictive Biomarker of Efficacy in NSCLC Patients Treated with Vandetanib Anderson Ryan
January 5, 2009 High Content Analysis Application of Novel Multiparametric High-Content Toxicity and Phenotypic Assays: Integration with Advances in Automation, Image Analysis, Multivariate Statistics and in silico Modeling Neil Carragher
Evaluation of Cellular Impedance Assays for Assessing Ligand-Specific GPCR Signaling in Drug Discovery Matt Peters
December 9, 2008 Informa Life Science’s annual Signal Detection& Risk Management Communicating drug safety to the public Bledar Hadëri,
December 4, 2008 BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008) Session Chair :Track 1-10 James Jianguo Li
Small Molecule Inhibitors Targeting Mutation Driven Cancers :Track 2-4 (I) Jeannie Hou
December 2, 2008 2nd Annual:Outsourcing Preclinical Development Risk analysis as a 'tool' for preclinical outsourcing selection Eva Ridley,
Outsourcing inhalation studies Paul Carter,
December 2, 2008 2nd Annual: Pre-clinical and clinical safety testing for new drugs Session 1:Why the industry is challenging the need for acute toxicity tests in the development of new medicines Sally , Robinson
What happens after positive ‘thorough’ QT studies? Corina-Dana Dota,
December 2, 2008 4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development 1: Modelling with 3D high-content cellular imaging in drug discovery Neil Carragher,
2 : How does imaging help? A thorough analysis of translating preclinical to clinical trials using imaging methods Harsukh , Parmar
2 : Successful implementation of fMRI (functional MRI) and phMRI (pharmacological MRI) in preclinical analgesia studies Jeremy Young,
2 : Panel Debate: How translatable is preclinical and clinical imaging? Harsukh , Parmar
December 2, 2008 The 8th World Drug Discovery & Development Summit 2008 Chairman's introduction Prof. Ian Wilson
IDENTIFYING HUMAN DRUG METABOLITES FOR TOXICITY TESTING - METABOLITES IN THE MIST Prof. Ian Wilson
STREAMLINING PROCESSES IN DISCOVERY AND DEVELOPMENT Clare Hammond
November 26, 2008 4th Annual Audits and Inspections for Clinical Trials and Pharmacovigilance Opening remarks from the Chairperson Brenda Scarth,
Closing remarks from the chairperson Brenda Scarth,
Opening remarks from the Chairperson Brenda Scarth,
Closing remarks from the chairperson Brenda Scarth,
Overcoming the challenges of clinical trials and audits and inspections in Japan Brenda Scarth,
November 26, 2008 Speed and Safety in Drug Discovery Humanising drug discovery to make earlier & better Stop/Go decisions in Pharma R&D Paul Newbold
November 17, 2008 BIO-Europe 2008 Critical Issues to Consider when Entering the U.S. Market and Partnering with U.S. Companies Chris Yochim
A Day in the Life of Experienced Dealmakers – Year 6! Shaun Grady
A Day in the Life of Experienced Dealmakers – Year 6! Shaun Grady
November 12, 2008 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements Co-Chairs’ Opening Remarks William Mongan
November 5, 2008 DIA's 6th Canadian Annual Meeting: Benefit and Risk Management: An Evolution in Progress TRACK 2 : PATIENT RISK MANAGEMENT PLANS: AN EU-US PERSPECTIVE Linda , Warner
TRACK 3 : DRUG SUBSTANCE DESIGN SPACE: APPLYING THE CONCEPTS Alan , Watt
October 21, 2008 Ion Channels as therapeutic targets Improving Ion Channel Lead Generation Capabilities by a Multi-Disciplinary Approach Michael Dabrowski
Progressing at an Accelerated Pace in Ion Channel Drug Discovery—Meeting the Top Two Challenges: Michael Dabrowski
October 20, 2008 Protein Expression Europe Comments by Session Chairperson Stefan R. Schmidt
Fusion-Proteins as Biopharmaceuticals: Applications and Challenges Stefan R. Schmidt
October 14, 2008 Crystal Form Selection and Crystallisation of API “Quality-by-design” of the crystallisation process Martin Böhlin
Using PAT to monitor and control the crystallisation process Sharon Bowden
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Fingerprint Based Methods for Predicting Sites of Metabolism C Scott Boyer
Relevance of In Vitro and In Vivo Models to Cardiovascular Toxicity Tim Hammond
October 8, 2008 Accelerating Proof Of Concept Biomarkers in Early Stage Drug Development: Challenges and Opportunities - The Changing Face of Early Drug Development at AstraZeneca Victor Sandor
September 29, 2008 Genomic Biomarkers Personalized Healthcare – Where Are We Now? Ruth E. March
September 29, 2008 Metabolic Biomarkers Metabolomics/Proteomics: Tools for Biomarker Discovery within Safety Assessment Johan Lindberg
June 19, 2008 Virtual Discovery Europe Computed Activity Discriminants for Compound Design and Virtual Screening Xincai Luo
April 28, 2008 Clinical Development of Therapeutic Antibodies Development of a New Fully Human Anti-CD20 Gadi Bornstein
Preclinical and Clinical Safety of Monoclonal Antibodies Richard Knight
March 31, 2008 China 2008 Pharmaceutical R&D Summit Track II Embarking on a Long March for Early Drug Development in China James Cai
March 18, 2008 MedChem India Drug Discovery Studies to Treat Tuberculosis Bala Ganesh Tanjore
December 4, 2007 7th World Drug Discovery & Development Summit 2007 BIOMARKERS AND PERSONALISED MEDICINE OF THE FUTURE Prof. Ian Wilson
December 3, 2007 PharmSep MAIN CONFERENCE INTERACTIVE TUTORIALS: A: Pre-Validation Characterization of LC-MS/MS Based Bioanalytical Methods Anders Olsson
N. Demystifying Supercritical Fluid Chromatography (SFC) for Chiral Separations: Analytical to Preparative Jennifer L. Van Anda
December 3, 2007 Pharma Sep MAIN CONFERENCE INTERACTIVE TUTORIALS: A: Pre-Validation Characterization of LC-MS/MS Based Bioanalytical Methods Anders Olsson
N. Demystifying Supercritical Fluid Chromatography (SFC) for Chiral Separations: Analytical to Preparative Jennifer L. Van Anda
November 29, 2007 Fourth Annual In Vivo Molecular Imaging: Bridging the Gap from Discovery to Clinical Applications Nov (29-30) Clinical Applications (13:40-17:30) Chi-Ming Lee
Clinical Applications: PET as a Translational Tool for CNS Drug Development (15:20-15:50) Chi-Ming Lee
November 28, 2007 Second Annual Portfolio Management: Creating a Portfolio for Optimal Productivity Nov (28-29) INTERACTIVE PANEL DISCUSSION: How Can We Translate These Lessons Learned from other industries into Helpful Tools for Pharma? (11:05-11:50) James F. Resch
November 27, 2007 Fifth Annual Strategic Resource Management: The Key to Increasing R&D Productivity Nov (27-28) ROUNDTABLE DISCUSSIONS TABLE 1: Optimizing Portfolio Value through Back-Up and Follow-Up Strategies (16:45-18:00) James F. Resch
November 26, 2007 Obesity Drug Development World 2007 Underscoring the need for new therapies with new mechanisms Håkan Wennbo
Glucokinase Activators in Diabetes Management: The discovery and pre-clinical evaluation of Glucokinase Activators (GKAs) Matthew Coghlan
Panel session: additional Q&A on SGLT2, GKA and GLP-1 Matthew Coghlan
November 7, 2007 Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13) Session 15: Anti-Cancer/Tumors Drug Discovery & Development and Current Status of the Innovative Therapeutics (Part III) (13:30-17:00) Xiaolin Zhang
Session 15: AZD1152, an Aurora B Kinase Inhibitor, Demonstrates Potent Antitumour Efficacy in Preclinical Models (16:15-16:40) Xiaolin Zhang
October 24, 2007 Virtual Discovery Europe Computer-Aided Drug Design And Screening Development of Grid Based Pharmacophore Toolkit Martin Harrison
October 16, 2007 Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies Oct (16-17) Clinical Trials (12:10-19:30) Robert Wilkinson
Clinical Trials: AZD1152, a Highly Potent and Selective Inhibitor of Aurora B Kinase (14:55-15:25) Robert Wilkinson
October 15, 2007 Cambridge Healthtech Institute's Third Annual Mastering Process Chemistry Oct (15-17) PROCESS OPTIMIZATION VIA ANALYTICS: Anticipation of Scale-Up Issues in Process Development: Scale Up Risk Evaluation (SURE) (16:35-17:05) Frans L. Muller
PROCESS OPTIMIZATION VIA ANALYTICS (14:00-15:05) Frans L. Muller
September 27, 2007 Protein Expression Europe (Sep 27-28) Protein Localization (13:25-16:15) Stefan R. Schmidt
Protein Localization: Comments by Session Chairperson (13:25-13:30) Stefan R. Schmidt
Breakfast BuzZ Sessions (08:00-09:00) Niek Dekker
Breakfast BuzZ Session IV: Sampling Expression Space (08:00-09:00) Niek Dekker
Drug Discovery Applications (13:00-15:15) Niek Dekker
Drug Discovery Applications: Purified Membrane Protein Targets for Drug Discovery (13:45-14:15) Niek Dekker
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Third annual Genomic Biomarkers: PHARMACOGENETICS: Major Pharmacogenetics Studies Using a Combination of Genome-Wide Tagging SNPs and High Density SNP Genotyping in Candidate Genes (10:05-10:35) Neil Gibson
Third annual Genomic Biomarkers: PHARMACOGENETICS (08:30-11:30) Neil Gibson
Eight Annual Metabolic Biomarkers: METABOLIC BIOMARKER DISCOVERY (08:30-11:00) Stephen Furlong
Eight Annual Metabolic Biomarkers; METABOLIC BIOMARKER DISCOVERY: Urine and Plasma Biomarkers in Schizophrenia (09:05-09:35) Stephen Furlong
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.